Print Article | Back to Articles

Cardiac complications associated with trastuzumab in the setting of adjuvant chemotherapy for early breast cancer overexpressing human epidermal growth factor receptor type 2 – a prospective study Archives of Medical Science, 05/10/2012

Piotrowski G et al. – One out of five treated patients discontinues trastuzumab in an adjuvant setting due to cardiac complications. LV dysfunction is the most frequent. Routine cardiac monitoring should be obligatory.

Read this article on Archives of Medical Science

Print Article | Back to Articles

Stay current on the latest literature, research and clinical news
Get special communications and offers from MDLinx and our sponsors
Receive invitations to paid market research

View Samples and Register

Stay current - Media Tool

Newsletter

RSS

Facebook

Receive free subspecialty
"5-minute updates" via email

Send the E-mail Newsletter to a Colleague

♦ Subscribe to our free RSS feeds:
Get the latest news in your specialty automatically added to your newsreader or your personal My Yahoo!, Google, My MSN or My AOL page. Learn More ♦

♦ Follow Us on Twitter
Twitter is a rich source of instantly updated information. Join today and follow @MDLinx to start receiving tweets. Learn More ♦

♦ Follow Us on Facebook

Search the latest
Internal Medicine Jobs
@MDLinx Career Center
View the full listing of physician jobs

Enter your email address and your password will be sent to you.
Email:

E-mail:
Password:
	Remember me Forgot your password?